Given where we are, with the potential for a pandemic, the clearest vision we can have is to dramatically increase the availability of this drug and make all information available.

Companies we identified to take the capacity further will therefore allow Roche’s supply network to respond to future demands from world governments.

We are pleased to announce the partnership with Hetero Drugs as the latest step in our scale-up efforts to meet the needs of governments in preparing for the potential public health threat posed by avian...

It presents a difficult target for clinical investigation.

As a result of a period of intense production planning, we are pleased to announce the partnership with Hetero Drugs as the latest step in our scale-up efforts to meet the needs of governments in...

If a company believes that they have the ability to do this from start to finish we would discuss that with them.

One of the issues faced in determining the background for any incident is determining the potential contribution of a drug or the contribution of the underlying illness.

To state that the drugs are not suitable for routine influenza control is entirely inappropriate, is inconsistent with regulatory opinions worldwide and is not supported by the data.

One of the very important things to point out here is that we are not dealing with a human pandemic strain yet, thank goodness.